Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma acts as a meaningful barrier to treatment entry and treatment provision. In the context of dramatically rising opioid-related harms, it is critical that we understand the drivers of stigma and how it affects opioid use disorder treatment and policy. The aim of this narrative review is to discuss how opioid-related stigma impacts treatment provision and harm reduction, and provide potential strategies to reduce stigma at a social and structural level. We used the Framework for Integrating Normative Influences on Stigma (FINIS) to identify sources of opioid-related stigma at the macro (structural stigma), meso (public stigma) and micro (internalised stigma) levels. Reducing stigma requires strategies that target multiple levels, however addressing inequity in the laws, regulations, and rules that segregate people with opioid and other substance use disorders from mainstream society is essential.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800858 | PMC |
http://dx.doi.org/10.2147/SAR.S304566 | DOI Listing |
AIDS Care
December 2024
International Health Program, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Voluntary medical male circumcision (VMMC) was identified as an effective strategy in HIV prevention. Although circumcision reduces heterosexual acquisition of HIV by 60%, there is low uptake of VMMC services in Eswatini. This study applies the health belief model (HBM) in understanding perceptions of young men in Eswatini towards VMMC for HIV prevention to upscale its adoption.
View Article and Find Full Text PDFBehav Brain Res
December 2024
Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-sen University, Sun Yat-Sen University, Shenzhen, China. Electronic address:
Introduction: Monoamine oxidase-B (MAO-B) inhibitors, as an add-on therapy to levodopa, are widely used in Parkinson's disease (PD). The effects of MAO-B inhibitors on quality of life remain unclear, and the aim of this systematic review and meta-analysis was to assess the efficacy and safety of MAO-B inhibitors on quality of life in different domains.
Methods: We searched PubMed, Embass, and Cochrane Library databases for randomized controlled trials of PD patients who were administered MAO-B inhibitors.
Am J Prev Med
December 2024
Departments of Epidemiology and Health Systems and Population Health, University of Washington, Seattle, WA; Department of Social and Behavioral Sciences, Yale University, New Haven, CT.
Introduction: Healthcare avoidance and delay (HAD) is prevalent among transgender (trans) populations. This study sought to identify patterns of HAD and examine associations between HAD and 5 behavioral health outcomes among trans adults: depression, anxiety, tobacco and alcohol use, and intimate partner violence (IPV).
Methods: This study used survey data collected in 2023 from 789 trans adults in Washington state.
Asian J Psychiatr
December 2024
Centre of Disease Control and Prevention Department, Hamad Medical Corporation, Qatar.
Child and adolescent mental health disorders in Qatar remain significantly underserved due to a critical shortage of specialists, stigma, and logistical barriers. This paper proposes implementing a Collaborative Care Model (CoCM) within Qatar's primary care settings, leveraging existing infrastructure, such as the CERNER electronic health record system, and innovations like telepsychiatry and AI-driven tools. The model integrates task-sharing among interdisciplinary teams to enhance accessibility and continuity of care.
View Article and Find Full Text PDFPsychol Health Med
December 2024
Department of Psychology, University of Nigeria, Enugu, Nigeria.
Despite extensive research on the impact of stigma on the health-related quality of life (HRQoL) of people with sickle cell disease, gaps remain in understanding the mechanisms through which this association occurs. We investigated how stigma impacts HRQoL among people with sickle cell disease (SCD) through distress and the moderating role of social support in this association. Utilizing a cross-sectional design, we sampled 165 people with SCD in Nigeria, who completed relevant measures.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!